© J. Poirier 2022
Although    there    are    a    few    medications    designed    to    improve memory   deficits   in AD   subjects,   none   of   these   treatments   halt   or slow   down   the   progression,   or   delay   onset   of   the   disease   in   a significant    manner.   At    best,    the    clinical    benefits    last    6    to    18 months,   and   only   in   a   modest   subset   of   patients.   Our   pioneering work   on   the   role   of   genetic   risk   factors   and   biomakers   in   disease etiology   and   therapy   has   allowed   us   to   identify   several   genetic variants    and    many    cerebrospinal    fluid    (CSF)    biomarkers    that affect   either,   the   age   of   onset,   the   rate   of   progression   or,   the quality of the drug response to memory enhancer medications. The    most    common    genetic    defect    identified    so    far    involves critical   transporters   of   brain   cholesterol   called   apolipoprotein   E (apoE),   J   and   B   ,   as   well   as   many   of   their   companion   proteins called ABCA1, ABCG1   and ABCA7,   BuChE,   FDPS,   GGDPS   and the   so-called   HMGCR.   Using   this   unique   genetic   and   proteomic information,   we   have   characterized   the   biological   functions   of these   key   cholesterol   transporter   &   modulators   in   the   brain   and screened    a    large    number    of    chemical    entities    capable    of modulating    synaptic    plasticity    and    restoring    brain    activity    of affected   AD   subjects.   This   pioneering   work   led   to   the   successful identification   of   several   potent   inducer   agents   which   have   been tested   in   pre-clinical   research,   one   of   which   in   phase   2   trials. Inflammation   and   cardiovascular   biomarkers   are   also   of   prime interest   in   our   research   program,   especially   for   their   role   in   the pre-symptomatic   phase   of   the   disease   in   subjects   who   are   at-risk of    developping    the    disease    because    of    a    parental    history    of Alzheimer’s disease.  
Research Experience and Opportunities
Research Tools Team Publications  Services and Expertises Team Tools Media Facts Patent Portfolio Team Publication List of key publications describing some of the core discoveries done in the ADGEN unit. Patent Portfolio List of key patents  covering ADGEN research team’s discoveries over the course of the past 25 years.
Since  1989 Franšais Franšais